PortfoliosLab logo
REAX vs. NVO
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between REAX and NVO is 0.35, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.4

Performance

REAX vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Real Brokerage Inc (REAX) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

40.00%60.00%80.00%100.00%120.00%140.00%160.00%180.00%December2025FebruaryMarchAprilMay
75.20%
73.86%
REAX
NVO

Key characteristics

Sharpe Ratio

REAX:

0.24

NVO:

-1.07

Sortino Ratio

REAX:

0.80

NVO:

-1.51

Omega Ratio

REAX:

1.09

NVO:

0.80

Calmar Ratio

REAX:

0.35

NVO:

-0.75

Martin Ratio

REAX:

0.61

NVO:

-1.46

Ulcer Index

REAX:

22.05%

NVO:

30.77%

Daily Std Dev

REAX:

56.21%

NVO:

42.23%

Max Drawdown

REAX:

-74.76%

NVO:

-71.29%

Current Drawdown

REAX:

-34.23%

NVO:

-51.94%

Fundamentals

Market Cap

REAX:

$897.21M

NVO:

$306.30B

EPS

REAX:

-$0.14

NVO:

$3.43

PS Ratio

REAX:

0.71

NVO:

0.99

PB Ratio

REAX:

27.91

NVO:

13.27

Total Revenue (TTM)

REAX:

$1.06B

NVO:

$225.05B

Gross Profit (TTM)

REAX:

$93.64M

NVO:

$190.45B

EBITDA (TTM)

REAX:

-$8.78M

NVO:

$113.24B

Returns By Period

In the year-to-date period, REAX achieves a -4.78% return, which is significantly higher than NVO's -18.22% return.


REAX

YTD

-4.78%

1M

4.04%

6M

-17.82%

1Y

7.62%

5Y*

N/A

10Y*

N/A

NVO

YTD

-18.22%

1M

10.68%

6M

-37.16%

1Y

-42.62%

5Y*

19.03%

10Y*

11.75%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

REAX vs. NVO — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

REAX
The Risk-Adjusted Performance Rank of REAX is 5959
Overall Rank
The Sharpe Ratio Rank of REAX is 6060
Sharpe Ratio Rank
The Sortino Ratio Rank of REAX is 5959
Sortino Ratio Rank
The Omega Ratio Rank of REAX is 5454
Omega Ratio Rank
The Calmar Ratio Rank of REAX is 6666
Calmar Ratio Rank
The Martin Ratio Rank of REAX is 5858
Martin Ratio Rank

NVO
The Risk-Adjusted Performance Rank of NVO is 66
Overall Rank
The Sharpe Ratio Rank of NVO is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of NVO is 55
Sortino Ratio Rank
The Omega Ratio Rank of NVO is 66
Omega Ratio Rank
The Calmar Ratio Rank of NVO is 77
Calmar Ratio Rank
The Martin Ratio Rank of NVO is 88
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

REAX vs. NVO - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Real Brokerage Inc (REAX) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for REAX, currently valued at 0.24, compared to the broader market-2.00-1.000.001.002.003.00
REAX: 0.24
NVO: -1.07
The chart of Sortino ratio for REAX, currently valued at 0.80, compared to the broader market-6.00-4.00-2.000.002.004.00
REAX: 0.80
NVO: -1.51
The chart of Omega ratio for REAX, currently valued at 1.09, compared to the broader market0.501.001.502.00
REAX: 1.09
NVO: 0.80
The chart of Calmar ratio for REAX, currently valued at 0.35, compared to the broader market0.001.002.003.004.005.00
REAX: 0.35
NVO: -0.75
The chart of Martin ratio for REAX, currently valued at 0.61, compared to the broader market-10.000.0010.0020.00
REAX: 0.61
NVO: -1.46

The current REAX Sharpe Ratio is 0.24, which is higher than the NVO Sharpe Ratio of -1.07. The chart below compares the historical Sharpe Ratios of REAX and NVO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.005.00December2025FebruaryMarchAprilMay
0.24
-1.07
REAX
NVO

Dividends

REAX vs. NVO - Dividend Comparison

REAX has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 2.33%.


TTM20242023202220212020201920182017201620152014
REAX
Real Brokerage Inc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
NVO
Novo Nordisk A/S
2.33%1.68%1.00%1.20%1.34%1.86%2.14%2.47%2.12%3.93%1.31%1.96%

Drawdowns

REAX vs. NVO - Drawdown Comparison

The maximum REAX drawdown since its inception was -74.76%, roughly equal to the maximum NVO drawdown of -71.29%. Use the drawdown chart below to compare losses from any high point for REAX and NVO. For additional features, visit the drawdowns tool.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%December2025FebruaryMarchAprilMay
-34.23%
-51.94%
REAX
NVO

Volatility

REAX vs. NVO - Volatility Comparison

The current volatility for Real Brokerage Inc (REAX) is 13.09%, while Novo Nordisk A/S (NVO) has a volatility of 18.14%. This indicates that REAX experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%December2025FebruaryMarchAprilMay
13.09%
18.14%
REAX
NVO

Financials

REAX vs. NVO - Financials Comparison

This section allows you to compare key financial metrics between Real Brokerage Inc and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00B40.00B60.00B80.00BAprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
350.63M
85.68B
(REAX) Total Revenue
(NVO) Total Revenue
Values in USD except per share items

REAX vs. NVO - Profitability Comparison

The chart below illustrates the profitability comparison between Real Brokerage Inc and Novo Nordisk A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
8.6%
84.8%
(REAX) Gross Margin
(NVO) Gross Margin
REAX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Real Brokerage Inc reported a gross profit of 29.99M and revenue of 350.63M. Therefore, the gross margin over that period was 8.6%.
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported a gross profit of 72.66B and revenue of 85.68B. Therefore, the gross margin over that period was 84.8%.
REAX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Real Brokerage Inc reported an operating income of -6.39M and revenue of 350.63M, resulting in an operating margin of -1.8%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported an operating income of 36.74B and revenue of 85.68B, resulting in an operating margin of 42.9%.
REAX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Real Brokerage Inc reported a net income of -6.64M and revenue of 350.63M, resulting in a net margin of -1.9%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported a net income of 28.23B and revenue of 85.68B, resulting in a net margin of 33.0%.